Researchers seek to re-purpose an existing manufacturing platform to produce a COVID-19 vaccine
Alan Rudolph, Colorado State University and Raymond P. Goodrich, Colorado State University
The Research Brief is a short take about interesting academic work.
The big idea
We are both biotechnology researchers and are currently seeking to repurpose an existing medical manufacturing platform to quickly develop a vaccine candidate for COVID-19.
This process is used for the treatment of blood products such as plasma, platelets and whole blood to prevent disease transmission when people receive transfused blood. It utilizes a common food ingredient, vitamin B2, or riboflavin, which is a light-sensitive chemical. When used in combination with ultraviolet light of specific wavelengths, B2 can alter genetic material, whether RNA or DNA, of infectious pathogens in the blood, making them unable to transmit disease.















